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PURPOSE. To correlate changes between VEGF expression with
systemic and retinal oxidative stress and inflammation in
rodent models of obesity induced insulin resistance and
diabetes.
METHODS. Retinal VEGF mRNA and protein levels were assessed
by RT-PCR and VEGF ELISA, respectively. Urinary 8-hydrox-
ydeoxyguanosine (8-OHdG), blood levels of C-reactive protein
(CRP), malondialdehyde (MDA), and CD11b/c positive cell
ratio were used as systemic inflammatory markers. Retinal
expression of Nox2, Nox4, and p47phox mRNA levels were
measured as oxidative stress markers. TNF-a, inter-cellular
adhesion molecule-1 (ICAM-1), IL1b, and activation of nuclear
factor jB (NF-jB) were used as retinal inflammatory markers.
RESULTS. Retinal VEGF mRNA and protein expression increased
in Zucker diabetic fatty (ZDFfa/fa) rats and streptozotosin (STZ)
induced diabetic Sprague-Dawley rats, after two months of
disease, but not in Zucker fatty (ZF) rats. Systemic markers of
oxidative stress and inflammation were elevated in insulin
resistant and diabetic rats. Some oxidative stress and inflam-
matory markers (TNF-a, IL-6, ICAM-1, and IL1-b) were
upregulated in the retina of ZDFfa/fa and STZ diabetic rats after
4 months of disease. In contrast, activation of NF-jB in the
retina was observed in high fat fed nondiabetic and diabetic cis-
NF-jBEGFP mice, ZF, ZDFfa/fa, and STZ-induced diabetic rats.
CONCLUSIONS. Only persistent hyperglycemia and diabetes
increased retinal VEGF expression. Some markers of inflam-
mation and oxidative stress were elevated in the retina and
systemic circulation of obese and insulin resistant rodents with
and without diabetes. Induction of VEGF and its associated
retinal pathologies by diabetes requires chronic hyperglycemia
and factors in addition to inflammation and oxidative stress.
(Invest Ophthalmol Vis Sci. 2012;53:8424–8432) DOI:
10.1167/iovs.12-10207
Diabetic retinopathy (DR) is observed in a majority ofdiabetic patients and is one of the most frequent causes of
blindness in the United States.1,2 Chronic hyperglycemia is
thought to be the primary cause of DR, as supported by the
Diabetes Control and Complications Trial and the United
Kingdom Prospective Diabetes Study.3,4 Sequential pathologic
changes in DR include increased vascular permeability,
pericyte apoptosis, acellular capillaries, and aberrant retinal
new vessel growth, or neovascularization.5 VEGF is one of the
most important endogenous angiogenic or permeability
inducing polypeptides that respond to hypoxia under normal
physiologic conditions.6,7 Elevated levels of VEGF in the
vitreous have been shown to correlate with the development
of diabetic macular edema and proliferative diabetic retinop-
athy (PDR).8,9 Further, treatments with VEGF inhibitors by
intravitreous injections have been shown to protect visual
acuity in diabetic macular edema and to regress neovascular-
ization in PDR.10,11 These findings have established VEGF
elevation in the ocular fluids and tissues as an important
validated marker for severe DR.
Previous reports have indicated that the induction of
oxidative stress and inflammation by abnormal metabolites
induced by diabetes may play a significant role in increasing
VEGF expression in the retina of diabetic patients or
animals.12–14 The addition of reactive oxygen species (ROS)
and inflammatory cytokines to vascular cells have also been
shown to induce VEGF expression.15 However, it is also well
established that obesity-induced insulin resistant states without
hyperglycemia will increase oxidative stress and inflammation
in many tissues and systemic circulation, yet vascular
pathologies of DR are rarely observed in obesity/insulin
resistant states without hyperglycemia.16,17 Thus, it is unclear
whether elevation of ROS and inflammation are observed in
the retina with obesity/insulin resistance and whether their
elevation alone in the retina will increase VEGF expression
without hyperglycemia.
In this study, we correlated the changes in systemic and
retinal inflammation and oxidative stress with VEGF expression
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in the retina of various rodent models of diabetes and insulin
resistance. The results suggested that inflammation or oxida-
tion can occur early in both obesity and diabetes, but chronic
exposure to hyperglycemia is essential for elevation of VEGF
expression in the retina.
METHODS
Animals and Induction of Diabetes
Nuclear factor jB (NF-jB)-dependent enhanced green fluorescent
protein (GFP) transgenic mice (cis-NF-jBEGFP) were produced as
described previously.18 Fourteen-week-old male Zucker diabetic fatty
rats (ZDFfa/fa) were used as models of obesity associated with type 2
diabetes, and Zucker nondiabetic lean rats (ZDFfa/þ) were used as their
age-matched controls (Charles River Laboratories, Wilmington, MA).
Six-month-old male Zucker fatty rats (ZF) and their age-matched lean
controls (ZL) were used as models of insulin resistance (Charles River
Laboratories). Diabetes was induced in C57/B6 mice and Sprague-
Dawley (SD) rats by injection of streptozotosin (STZ; 55 mg/kg body
weight), in 0.05 M/L citrate buffer (pH 4.5) or citrate buffer for
controls, (Sigma-Aldrich, St. Louis, MO). Blood glucose levels were
determined 2 days after the injections by glucose analyzer (Yellow
Spring Instruments, Yellow Springs, OH). Glycemic levels of greater
than 16.7 mM/L were defined as having diabetes. Obesity and insulin
resistance in 8-week-old cis-NF-jBEGFP mice were induced by a high fat
diet, 42% from fat, for an additional 8 weeks prior to sacrifice (Harlan
Teklad, Indianapolis, IN). All procedures involving animals conformed
to the Association for Research in Vision and Ophthalmology resolution
on the use of animals in research and were approved by the Animal Use
and Care Committee of Joslin Diabetes Center.
RT-PCR Analysis for Retinal RNA Expressions
Total RNA were isolated and purified from the retina by RNAeasy micro
column with DNase treatment (Qiagen, Inc., Valencia, CA) and cDNA
was synthesized using high capacity cDNA synthesis kit (Applied
Biosystems, Foster City, CA) or SuperScript III reverse transcriptase
(Invitrogen, Carlsbad, CA). The number of copies of transcript of VEGF
(Forward: AGC CAG AAA ATC ACT GTG AGC C; Reverse: TTT AAC
TCA AGC TGC CTC GCC; Probe: FAM-TGT TCC TGC AAA AAC ACA
GAC TCG CGT TG-TAMRA), Nox2 (Forward: CAG TGC GTG TTG CTC
AAC CAG AAT; Reverse: CAA TGG TGT GAA TGG CCG TGT GAA;
Probe: FAM-TCG AAG ACA ACT GGA CAG GAA CCT TAC T-TAMRA),
tumor necrosis factor-a (TNF-a) (Forward: TCT GTG CCT CAG CCT
CTT CTC ATT; Reverse: AAC TGA TGA GAG GGA GCC CAT TTG;
Probe: FAM-ATC GGT CCC AAC AAG GAG GAG AAG TT-TAMRA),
ICAM-1 (Forward: ACA GCA GAC CAC TGT GCT TTG AGA; Reverse:
ACT CGC TCT GGG AAC GAA TAC ACA; Probe: FAM-AGT CCT CGG
CTT CTG CCA CCA TCA-TAMRA), and rat IL1b (Forward: TGCAGGC
TTCGAGATGAAC; Reverse: GGGATTTTGTCGTTGCTTGTCR) in the
retina were measured using Applied Biosystems (ABI) Taqman real-time
PCR (Applied Biosystems). The p47phox (Forward: GTG AAG CCA
TCG AGG TCA TTC; Reverse: CCC GCG GCT TCT AAT CTG T), Nox4
(Forward: GAA CCT CAA CTG CAG CCT GAT C; Reverse: CTT TTG
TCC AAC AAT CTT CTT GTT CTC), IL-6 (Forward: CTT CAA TCC AGT
TGC CTT CTT G; Reverse: AAT TAA GCC TCC GAC TTG TGA AG),
gapdh (Forward: ATG TTC CAG TAT GAC TCC ACT CAC G; Reverse:
GAA GAC ACC AGT AGA CTC CAC GAC A) mRNA expressions in the
retina were evaluated by SYBR Green procedure (Applied Biosystems).
Amplification and detection were performed using the ABI PRISM 7900
Sequence Detection System (Applied Biosystems).
Urinary 8-OHdG, Plasma MDA, and Plasma CRP
Urinary 8-Hydroxydeoxyguanosine (8-OHdG) excretion was measured
by new 8-OHdG Check ELISA Kit (Nikken Seil Co., Ltd., Shizuoka,
Japan). Plasma malondialdehyde (MDA) and plasma C-reactive protein
(CRP) concentrations were measured by Lipid Peroxidation Assay Kit
(Oxi International, Inc., Foster City, CA) and by CRP, Rat Quantitative
Kit (Helica, Fullerton, CA), respectively.
Monocyte Activation in Peripheral Blood
Peripheral blood was drawn from the abdominal large vein by
heparinized syringe. Fresh drawn blood was treated by BD Pharm
Lyse lysing solution (BD Biosciences, San Diego, CA) for 15 minutes to
exclude red blood cells. Isolated leukocytes were used to analyze the
monocyte activation by fluorescence-activated cell sorting (FACS) for
the two color flow cytometry analysis, mouse PE-conjugated anti-rat
CD11b/c monoclonal antibody, PE-conjugated mouse Immunoglobulin
(IgG) 2a, j isotype control (BD Biosciences) were used. Flow
cytometry was performed on a BeckmanCoulter XL-MCL (Beckman-
Coulter, Fullerton, CA). The percentage of population was calculated
by the positive cell number in the total mononuclear cell number. Data
were analyzed by Expo32 (BeckmanCoulter).
Immunoblot Analysis, VEGF ELISA, and NF-jB p65
DNA Binding Assay
Nuclear-specific proteins were isolated using the compartmental protein
extraction kit (Millipore, Billerica, MA) according to the manufacturer’s
instructions. Samples were dissolved in 0.5% NP-40, used after
optimization studies. Proteins were separated by SDS-PAGE. Blots were
subsequently incubated with anti–NF-jB (p65) (Santa Cruz Biotechnol-
ogies, Santa Cruz, CA) and anti-PCNA (Cell Signaling, Beverly, MA).
Labeled protein bands were identified with enhanced chemiluminescent
system (Amersham Biosciences, Piscataway, NJ). VEGF protein was
measured by VEGF ELISA kit (R&D Systems, Minneapolis, MN).
Retina was homogenized and extracted protein was used in VEGF
ELISA assay. The data were normalized to protein level. NF-jB p65
activation (DNA binding activity) was assessed using NF-jB p65
Transcription Factor Kit as per manufacturer’s instructions (Pierce
Biotechnology, Rockford, IL).
Data Analysis
The data are expressed as mean 6 SD. Comparison among more than
two groups was performed by one-way ANOVA followed by the analysis
with paired or unpaired t test to evaluate statistical significance
between the two groups. All analyses were performed using StatView
(SAS Institute, Cary, CA). Statistical significance was defined as P less
than 0.05.
RESULTS
Physiologic Characteristics of Experimental
Groups
Body weights of ZF rats were greater than ZL rats by 2.1 6 0.6-
fold. Plasma insulin, cholesterol, free fatty acids, and triglycer-
ide levels of ZF rats were elevated by 1.7 6 0.2-fold, 5.3 6 1.4-
fold, 3.0 6 0.7-fold, and 9.1 6 3.8-fold, respectively, compared
with ZL rats (P < 0.05, Table 1). In the ZDFfa/fa rats, a type 2
diabetic model, blood levels of glucose, cholesterol, and
triglycerides were increased by 4.5 6 1.5-fold, 1.8 6 0.2-fold,
and 7.2 6 2.2-fold, respectively, compared with ZDFfa/þ
nondiabetic rats (P < 0.05, Table 1). After induction of
diabetes in Sprague-Dawley rats for 2 months, body weights of
diabetic Sprague-Dawley rats were significantly less than the
nondiabetic Sprague-Dawley rats by 20 6 5% and insulin was
decreased by 93 6 10% in diabetic Sprague-Dawley rats
compared with nondiabetic Sprague-Dawley rats (P < 0.05,
Table 1). The final body weights of Sprague-Dawley diabetic
rats were still greater than their initial weights indicating that
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the difference in body weights were not due to starvation.
Blood glucose levels were significantly elevated in diabetic
Sprague-Dawley rats at 559 6 57 mg/dL and 473 6 82 mg/dL
at 2 and 4 months, respectively.
VEGF Expression in the Retina
The expression of VEGF-b mRNA levels were elevated in the
retina of diabetic ZDFfa/fa, which have had diabetes for 8 weeks
compared with nondiabetic ZDFfa/ rats by 1.6 6 0.2-fold (P <
0.05, Fig. 1). Retinal VEGF protein levels were 34.3 6 12.4 pg/
mg protein in diabetic ZDFfa/fa versus 16.2 6 2.2 pg/mg in
nondiabetic control ZDFfa/ rats (P < 0.05, Fig. 1B). In contrast,
no differences in VEGF-b mRNA or protein expression were
detected between ZL and ZF rats. In Sprague-Dawley rats, the
induction of diabetes did not significantly increase VEGF-b
mRNA expression until after 2 months of diabetes by 1.3 6 0.3-
fold (P < 0.05, Fig. 1), which persisted at 4 months of diabetes
by 1.4 6 0.2-fold (P < 0.05, Fig. 1). No significant increases in
retinal VEGF-b mRNA expression were observed after 1 month
of diabetes in Sprague-Dawley rats. Consistent with the mRNA
levels, retinal VEGF protein significantly increased at 4 months
(diabetic 26.2 6 3.5 pg/mg versus nondiabetic rats 21.4 6 4.2
pg/mg (P < 0.05, Fig. 1B).
Systemic Oxidative Stress and Inflammation in the
Experimental Groups
Systemic markers of oxidative stress and inflammation were
assessed in fatty and diabetic rats and compared with their





(Diabetic) Cont. (2M) STZ (2M) Cont. (4M) STZ (4M)
Number 7 7 6 6 5 5 7 7
Body weight, g 400 6 20 830 6 130* 385 6 6 406 6 5‡ 283 6 6 226 6 13|| 475 6 29 355 6 20#
Blood glucose, g 90 6 10 99 6 13 89 6 11 402 6 16§ 151 6 5 559 6 57¶ 128 6 24 473 6 82**
Insulin, ng/mL 5.2 6 2.6 36 6 3† 4.0 6 0.9 2.4 6 0.9 4.3 6 1.6 0.3 6 0.1¶ ND ND
FFA, mEq/L 0.4 6 0.2 1.3 6 0.1† ND ND ND ND ND ND
T-Cho, mg/dL 57 6 7 474 6 50† 44 6 14 75 6 37‡ 21 6 12 38 6 27 ND ND
TG, mg/dL 131 6 10 1198 6 80† 38 6 2 275 6 21§ 0.9 6 0.7 2.1 6 2.3 ND ND
Cont., nondiabetic Sprague-Dawley rats; ND, not done; FFA, free fatty acids; T-Cho, total cholesterol; TG, triglycerides. The data are expressed as
the mean 6 SD.
* P < 0.05.
†P < 0.001 versus ZL rats.
‡ P < 0.05.
§P < 0.001 versus ZDFfa/þ lean rats.
|| P < 0.05.
¶P < 0.001 versus nondiabetic Sprague-Dawley rats (2M).
# P < 0.05.
**P < 0.001 versus nondiabetic Sprague-Dawley rats (4M).
FIGURE 1. Expression of VEGF mRNA and protein in the retina. VEGF mRNA (A) and protein expression (B) in the retina of ZL, ZF, ZDFfa/þ lean,
ZDFfa/fa, nondiabetic Sprague-Dawley and STZ-induced diabetic Sprague-Dawley rats after several months of disease duration. *P < 0.05 versus
ZDFfa/þ lean rats. †P < 0.05 versus nondiabetic Sprague-Dawley rats (2M). ‡P < 0.05 versus nondiabetic Sprague-Dawley rats (4M). One of three
independent experiments is shown. These data are expressed as mean 6 SD. NS, not significant; STZ, STZ-induced diabetic Sprague-Dawley rats; M,
months.
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respective controls. Oxidative stress markers as measured by
plasma MDA levels were significantly increased in ZF, ZDFfa/fa,
and diabetic Sprague-Dawley rats with 2 months of diabetes by
1.6 6 0.3-fold, 2.1 6 0.8-fold, and 1.7 6 0.4-fold, respectively,
when compared with ZL, ZDFfa/þ lean and nondiabetic
Sprague-Dawley rat controls (P < 0.05, Table 1). Similar to
MDA, urinary oxidative stress markers 8-OHdG excretion was
also increased in ZF, ZDFfa/fa, and diabetic Sprague-Dawley rats
with 2 months of diabetes by 2.6 6 1.2-fold, 8.0 6 2.1-fold,
and 4.4 6 1.3-fold, respectively, when compared with ZL,
ZDFfa/þ lean and nondiabetic Sprague-Dawley rats (P < 0.05,
Table 2).
Several systemic inflammatory markers were assessed
including circulating monocyte activation using CD11b/c
labeling and plasma CRP levels. Circulating monocytes positive
for CD11b/c, as measured by FACS, were increased in ZF,
ZDFfa/fa, and diabetic Sprague-Dawley rats by 1.9 6 0.4-fold,
2.6 6 0.2-fold, and 1.8 6 0.5-fold, respectively, when
compared with ZL, ZDFfa/þ lean and nondiabetic Sprague-
Dawley rats with 2 months of diabetes (P < 0.05, Table 1).
Similarly, plasma levels of CRP were also increased in ZF and
ZDFfa/fa rats by 1.3 6 0.5-fold and 1.2 6 0.1-fold, respectively,
when compared with ZL and ZDFfa/þ lean rats. In contrast,
plasma CRP levels were not significantly increased in Sprague-
Dawley rats with 2 months of diabetes compared with Sprague-
Dawley nondiabetic rats (P < 0.05, Table 1).
Characterization of Inflammatory Markers in the
Retina
Markers of inflammation in the retina with the induction of
diabetes or insulin resistant states were characterized. Expres-
sion of TNF-a mRNA levels were not increased in the retina of
ZF rats when compared with ZL rats after 2 months on the fatty
diet. In contrast, TNF-a mRNA levels were elevated in the
retinas of ZDFfa/fa rats compared with nondiabetic ZDFfa/ rats.
For Sprague-Dawley rats, the induction of diabetes by STZ for 1
and 2 months did not increase TNF-a mRNA levels in the
retina, but, 4 months of diabetes did increase its levels by 3.0
6 1.4-fold (P < 0.05, Fig. 2A). Similarly, IL-6 mRNA expression
was not increased in the retina of ZF rats after 1 month of
diabetes, but it did elevate significantly in the retina of ZDFfa/fa
rats, after 2 and 4 months of diabetes and in Sprague-Dawley
rats by 2.8 6 0.3-fold and 9.0 6 1.5-fold, respectively (P <
0.05, Fig. 2B). ICAM-1 mRNA expression was not increased in
the retina of ZF rats, or after 1 month and 2 months of diabetes
in Sprague-Dawley rats. However, ICAM-1 mRNA expression
was increased in the retina of diabetic ZDFfa/fa rats and
Sprague-Dawley rats after 4 months of diabetes by 2.8 6 1.3-
fold and 5.3 6 1.8-fold, respectively (P < 0.05, Fig. 2C). Auto-
inflammatory marker IL1b mRNA increased significantly after 4
months of diabetes in Sprague-Dawley rats (P < 0.05, Fig. 2D).
Retinal IL1b mRNA levels did not differ between ZL and ZF
rats. In contrast, levels of IL1b mRNA were increased by 1.6 6
0.3-fold in diabetic ZDFfa/fa rats versus controls (P < 0.05, Fig.
2D).
Evaluation of Oxidative Stress Markers in the
Retina
Expression of mRNA levels of NOX2, NOX4, and p47phox,
assessed in the retina were not changed in insulin resistant ZF
rats compared with their ZL controls. In contrast, the mRNA
levels of NOX2, NOX4, and p47phox were elevated signifi-
cantly by 2.5 6 0.4-fold, 1.3 6 0.1-fold, and 2.2 6 0.7-fold in
ZDFfa/fa compared with nondiabetic ZDFfa/wt rats. In diabetic
Sprague-Dawley rats, mRNA levels of NOX2 and NOX4 were
not significantly elevated until 4 months of diabetes. For
p47phox mRNA levels, significant elevations of 1.5 6 0.6-fold
and 3.1 6 1.2-fold were noted in the retina of diabetic Sprague-
Dawley rats after 2 and 4 months of diabetes, respectively, but
not after 1 month of disease.
Involvement of NF-jB Activation in the Retina
Previous reports have indicated that both increase in
inflammatory cytokines and oxidants are associated with
NF-jB activation, especially with diabetes or insulin resis-
tance.12,19 In addition, high glucose levels can activate NF-jB
in retinal vascular cells.20 Thus, we evaluated whether the
expression of p65 subunit of NF-jB, a marker of its activation,
was increased in the retina of various diabetic and insulin
resistant rodent models. Immunoblot study showed increases
in p65 subunit of NF-jB in the retina of ZF rats, ZDFfa/fa rats,
and diabetic Sprague-Dawley rats of 4 months duration by 3.6
6 0.3-fold, 4.6 6 0.4-fold, and 6.4 6 0.2-fold, respectively,
when compared with ZL, ZDFfa/þ lean, and nondiabetic
Sprague-Dawley rats (P < 0.05, Fig. 4A). We also evaluated the
effect of insulin resistance and diabetes in cis-NF-jBEGFP mice,
which will increase GFP expression in tissues that activated
NF-jB.21 After 2 months of high fat feeding to induce obesity
without diabetes or 2 months of STZ-induced diabetes, GFP
positive areas in the retina of cis-NF-jBEGFP mice increased by
5.8 6 2.8-fold and 5.6 6 2.0-fold, respectively (P < 0.05, Fig.
4B). The findings of NF-jB activation were further confirmed
by the measurement of NF-jB DNA binding activity, which
were significantly increased in high fat feeding mice, ZF and
ZDFfa/fa compared with their respective control groups (P <
0.05, see Supplementary Material and Supplementary Fig. S1,
http://www.iovs.org/lookup/suppl/doi:10.1167/iovs.
12-10207/-/DCSupplemental). These results suggest that both
diabetes and insulin resistance can activate NF-jB in the
retina.





(diabetic) Cont. (2M) STZ (2M)
Number 7 7 6 6 5 5
MDA, lM 0.7 6 0.1 1.1 6 0.3* 1.2 6 0.5 2.5 6 0.6† 0.9 6 0.2 1.6 6 0.5‡
CRP, mg/mL 303 6 45 385 6 83* 334 6 55 392 6 55† 252 6 57 290 6 70
CD11b/c positive population, % 15.3 6 1.5 39.7 6 8.6* 15.6 6 1.7 29.5 6 3.8† 13.1 6 3.5 23.8 6 6.6‡
Urinary 8-OHdG, ng/d 144 6 64 381 6 107* 325 6 113 2603 6 1130† 267 6 119 1188 6 334‡
The data are expressed as the mean 6 SD.
* P < 0.05 versus ZL rats.
† P < 0.05 versus ZDFfa/þ lean rats.
‡ P < 0.05 versus nondiabetic Sprague-Dawley rats (2M).
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DISCUSSION
This study correlated, for the first time, changes in systemic
and retinal indices of oxidative stress and inflammation
associated with either diet induced insulin resistance or
diabetes on retinal VEGF expression. Past studies have focused
mainly on the activation of these pathways by diabetes alone
and their correlation to increasing retinal VEGF expression,
which is a pathogenic marker for diabetic macular edema and
proliferative retinopathy.2,8,9,22–25 The elevated expression of
FIGURE 2. Evaluation of retinal inflammation. Effect of diabetes and insulin resistance on the levels of various inflammatory markers in the retina.
TNF-a mRNA (A), IL-6 (B), ICAM-1 (C), and IL1b (D) expressions in the retina of ZL, ZF, ZDFfa/þ lean, ZDFfa/fa, nondiabetic Sprague-Dawley, and STZ-
induced diabetic Sprague-Dawley rats. *P < 0.05 versus ZDFfa/þ lean rats. †P < 0.05 versus nondiabetic Sprague-Dawley rats (2M). ‡P < 0.05 versus
nondiabetic Sprague-Dawley rats (4M). Results of three independent experiments are shown. These data are expressed as mean 6 SD.
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VEGF in the retina or vitreous is the only retinal molecular
marker of DR, which has been validated by clinical trials using
anti-VEGF therapy.10,11 Multiple studies have associated chang-
es in oxidative stress and inflammation with various retinal
changes including elevated VEGF expression in DR, in animal
models of diabetes, or in retinal vascular cells exposed to
elevated glucose levels.13,14,24–28 However, it has not been
established that these changes are essential or additive for
inducing elevated retinal VEGF expression by diabetes in vivo.
The results from this comparative analysis in rodent models
of diabetes and obesity associated insulin resistance showed
that VEGF expression in the retina was only induced by
diabetes, but not by obesity or insulin resistant states alone
where hyperglycemia is not present. Surprisingly, the increases
in VEGF expression were not observed until after 2 months of
diabetes and were not significant in obese rats (ZF) without
diabetes even though systemic markers of oxidative stress and
inflammation were clearly elevated. The finding of elevated
systemic inflammation markers and oxidative stress in insulin
resistant states and diabetes are not surprising since obesity,
hyperlipidemia, and elevated free fatty acids, in addition to
hyperglycemia, have all been reported to induce the expres-
sion of inflammatory cytokines, toll-like receptors, and oxidant
formation in many tissues including the blood vessels.16,29,30
We only studied ZF rats at 24 to 26 weeks, which may not be
long enough to detect changes in retinal VEGF expression.
However, it is likely that obesity and insulin resistance without
diabetes will cause significant VEGF elevation since it is very
rare that obese patients with metabolic syndrome, but without
diabetes develop macular edema or proliferative diabetic
retinopathy.
Elevation of retinal VEGF expression correlated only with
increased levels of inflammatory cytokines and oxidases in the
retina after they persisted for 2 to 4 months. This is clearly
supported by the elevation of all the indicators of oxidative
stress and inflammation in ZDF rats and STZ diabetic rats only
after 4 months of disease duration. At 2 months of disease
duration, some evidence of increased systemic oxidative stress
and inflammation were present such as the elevation of
p47phox in the retina, which correlated with increases in
VEGF expression. In contrast to measurements of inflammato-
ry cytokines and oxidative stress, diabetes was able to induce
FIGURE 3. Evaluation of oxidative stress in the retina. Characterization of changes in mRNA levels of Nox2 (A), Nox4 (B), and p47phox (C)
expressions in the retina of ZL, ZF, ZDFfa/þ lean, ZDFfa/fa, nondiabetic Sprague-Dawley, and STZ-induced diabetic Sprague-Dawley rats. *P < 0.05
versus ZDFfa/þ lean rats. †P < 0.05 versus nondiabetic Sprague-Dawley rats (2M). ‡P < 0.05 versus nondiabetic Sprague-Dawley rats (4M). Results of
three independent experiments are shown. These data are expressed as mean 6 SD.
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NF-jB activation in the retina as measured by both the binding
and activation assays and NF-jB–GFP expression at 2 and 4
months of diabetes and in ZDF rats. However, our results
clearly showed that insulin resistance and obesity without
diabetes and hyperglycemia also activated NF-jB and possibly
inflammation in the retina and shown in Figure 4 using ZF rats
and high fat fed mice for 2 months. It is not surprising that
insulin resistance or obesity could also induce inflammatory
changes in the retina, since, it was previously reported that
increases in leucocyte adhesion can be observed in both the
retinal and systemic vessels in obese and insulin resistant
animals similar to those observed in diabetes.14,31,32 These
increases in leucocyte adhesion are correlated with the
elevation of ICAM expression or inflammation markers.33,34
Thus, it is possible that increases in inflammation or oxidative
stress alone are not sufficient to induce VEGF expression in
vivo, without the presence of additional severe capillary
endothelial dysfunction to induce hypoxia or decrease retinal
perfusion induced by diabetes. These data also suggest that
diabetes or hyperglycemia is activating other pathologic
changes besides NF-jB, inflammation, or oxidative stress that
will lead to capillary dysfunction and acellular capillaries. This
conclusion is supported by clinical data, which clearly indicate
that specific vascular lesions of diabetic retinopathy are rarely
detected in people with obesity and severe insulin resistance
without diabetes, although they clearly can manifest inflam-
mation markers and oxidative stress.17,18 In addition, there are
multiple diseases, which cause inflammation of the vascula-
ture, yet they don’t manifest retinal vascular lesions similar to
DR.35 These findings strongly support the idea that hypergly-
cemia or diabetes is essential for the development of DR, and
its progression requires hyperglycemia to activate mechanisms
in addition to inflammation and oxidative stress. It is also
possible that other metabolic changes induced specifically by
diabetes could also play a role with hyperglycemia to induce
changes in VEGF expression.
The presence of hyperglycemia in inducing retinal VEGF
expression is clearly very important, which is likely due to its
adverse effects on retinal pericytes and endothelial cells to
cause pericyte apoptosis, acellular capillaries, and reduction in
retinal perfusion.5,20,35–38 However, unlike pericyte apoptosis,
the formation of acellular capillaries may not be specific to DR
since other inhibitors such as ischemic reperfusion may also
induce acellular capillary formation. Previously, we have
reported ZF rats, derived from a different rodent colony,
which had mean plasma glucose levels that were significantly
higher, by 50%, than its control ZL rats, had significant
increases in VEGF expression.39 In contrast, the mean plasma
glucose levels in the present study were not different between
ZL and ZF rats, resulting in the lack of VEGF levels being
elevated. These data again supported the necessity of
hyperglycemia to cause significant retinal vascular pathologies
in order to induce VEGF expression in the retina. We have
reported that one potential mechanism to induce pericyte
dysfunction and apoptosis, independent of oxidative and
inflammatory stress, is the activation of SHP-1 by hyperglyce-
mia.40 The activation of SHP-1, a tyrosine phosphatase, which
can be induced by hyperglycemia and PKC-d, inhibited the
actions of platelet derived growth factor, a pericyte survival
factor, causing pericyte apoptosis by mechanisms independent
of inflammation, oxidative stress and NF-jB.40
FIGURE 4. Activation of NF-jB in the retina of insulin resistant and diabetic rodents. (A) Representative immunoblots of NF-jB (p65) from retinal
nuclear proteins of ZL, ZF, ZDFfa/þ, diabetes ZDFfa/fa, control, and STZ diabetic Sprague-Dawley rats. Data from three experiments were quantitated
by densitometry. *P< 0.05 versus ZL rats. †P < 0.05 versus ZDFfa/þ lean rats. ‡P < 0.05 versus nondiabetic Sprague-Dawley rats (4M). Gel is from one
of three independent experiments. These data are expressed as mean 6 SD. (B) Activation of NF-jB in the retina of cis-NF-jBEGFP transgenic mice.
cis-NF-jBEGFP mice were fed a high fat diet for two months or had diabetes induced by STZ for two months, EGFP fluorescence was assessed using
digital fluorescence microscopy. Retina was digitally photographed, and the images were imported into Image-J software (National Institutes of
Health) and analyzed morphometrically. *P < 0.05 versus control mice (2M). One of three independent experiments is shown. The results from
three independent experiments were quantitated and expressed as mean 6 SD. HF, high fat feeding mice.
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In summary, both hyperglycemia and obesity related insulin
resistance can elevate systemic and retinal oxidative stress and
inflammation. However, hyperglycemia or diabetes are neces-
sary to increase retinal VEGF expression, possibly by activating
additional mechanisms that can induce significant capillary
pathology, hypoperfusion, and hypoxia. Thus, future effective
therapeutic interventions for diabetic retinopathy will require
neutralizing hyperglycemia’s multiple adverse effects in
addition to anti-oxidative and anti-inflammatory agents.
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